Advertisement

Drug Investigation

, Volume 2, Supplement 2, pp 40–47 | Cite as

Switch from Gemfibrozil to Lovastatin (Mevinolin) Therapy in Patients with Primary Hypercholesterolaemia

A Multicentre Study
  • Jukka-Pekka Ojala
  • E. Helve
  • M. J. Tikkanen
  • A. Jäättelä
  • E. Kaarsalo
  • A. Lehtonen
  • H. Oksa
  • P. Pääkkönen
  • J. Salmi
  • S. Snapinn
  • T. Veharanta
  • J. Viikari
Section 2: Efficacy of HMG CoA Reductase Inhibitors

Summary

This comparative study was designed to evaluate the changes in lipids and lipoprotein profiles in 141 hypercholesterolaemic patients with normal or moderately elevated triglycerides who were switched to lovastatin (mevinolin) therapy after 12 weeks of treatment with gemfibrozil 600mg twice daily. In stratum 1 (serum cholesterol 6.2–7.79 mmol/ L [n = 43]), patients started with lovastatin 20 mg/day and in stratum 2 (serum cholesterol ≥ 7.8 mmol/L [n = 98]) with lovastatin 40 mg/day. If serum cholesterol remained above 5.0 mmol/L after 6 weeks, the dose was doubled. Lovastatin produced a significantly greater fall in low density lipoprotein cholesterol both with the initial doses at 6 weeks (stratum 1: 29%; stratum 2: 35%) and with the increased doses at 12 weeks (stratum 1: 35%; stratum 2: 42%), compared with gemfibrozil (stratum 1: 13%; stratum 2: 17%). Although both drugs decreased serum triglyceride levels, gemfibrozil was much more effective. Both drugs increased high density lipoprotein (HDL)-cholesterol concentrations, the increases during gemfibrozil therapy ranging from 18% (stratum 1) to 11% (stratum 2) and during lovastatin therapy from 10% (stratum 1) to 8% (stratum 2). The total cholesterol: HDL-cholesterol ratio was reduced significantly more by lovastatin than by gemfibrozil, except with the smallest lovastatin dose.

Keywords

Serum Cholesterol Lovastatin Gemfibrozil Parallel Study Probucol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Evans JR, Forland SC, Cutler RE. The effect of renal function on the pharmacokinetics of gemfibrozil. Journal of Clinical Pharmacology 27: 994–1000, 1987PubMedGoogle Scholar
  2. Finley PR, Schifman RB, Williams RJ, Lichti DA. Cholesterol in high-density lipoprotein: use of Mg2+/dextran sulfate in its enzymic measurement. Clinical Chemistry 24: 931–933, 1978PubMedGoogle Scholar
  3. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentrations of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18: 499–502, 1972PubMedGoogle Scholar
  4. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. New England Journal of Medicine 318: 81–86, 1988PubMedCrossRefGoogle Scholar
  5. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. New England Journal of Medicine 319: 24–33, 1988PubMedCrossRefGoogle Scholar
  6. Havel RJ, Hunninghake DB, Illingworth DR, Lees RS, Stein EA, et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multicenter study. Annals of Internal Medicine 107: 609–615, 1987PubMedGoogle Scholar
  7. Helve E, Tikkanen MJ. Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. Atherosclerosis 72: 189–197, 1988PubMedCrossRefGoogle Scholar
  8. Hoeg JM, Maher MB, Bailey KR, Brewer Jr HB. The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia. Atherosclerosis 60: 209–214, 1986PubMedCrossRefGoogle Scholar
  9. Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia: a multicenter study. Journal of the American Medical Association 256: 2829–2834, 1986CrossRefGoogle Scholar
  10. Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. Journal of the American Medical Association 260: 359–366, 1988CrossRefGoogle Scholar
  11. Lovastatin Study Group IV. A comparison of lovastatin and probucol for treatment of primary hypercholesterolemia. Arteriosclerosis 8: 587a, 1988Google Scholar
  12. National Cholesterol Education Program Expert Panel. Report of the national cholesterol education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Archives of Internal Medicine 148: 36–69, 1988CrossRefGoogle Scholar
  13. Tikkanen MJ, Helve E, Jäättelä A, Kaarsalo E, Lehtonen A, Finnish Lovastatin Study Group, et al. Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish multicenter study. American Journal of Cardiology 62: 35J–43J, 1988PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1990

Authors and Affiliations

  • Jukka-Pekka Ojala
    • 1
  • E. Helve
    • 1
  • M. J. Tikkanen
    • 1
  • A. Jäättelä
    • 1
  • E. Kaarsalo
    • 1
  • A. Lehtonen
    • 1
  • H. Oksa
    • 1
  • P. Pääkkönen
    • 1
  • J. Salmi
    • 1
  • S. Snapinn
    • 1
  • T. Veharanta
    • 1
  • J. Viikari
    • 1
  1. 1.First and Third Department of MedicineUniversity of HelsinkiFinland

Personalised recommendations